Biobanking Market Growing at 6.6% CAGR to Touch US$ US$ 89.5 Billion Valuation by 2033: Fact.MR Report

The global biobanking market (バイオバンキング市場) is projected to grow at a strong compound annual growth rate of 6.6% by 2023 to 2033, reaching a sales valuation of US$ 89.5 billion. Globally, China, the UK, and the US are the key markets that biobanking enterprises need to be aware of.

By storing and preserving biological samples like blood, tissues, and nucleic acids, biobanking plays a crucial part in improving biomedical and translational research. These samples are then made available for use in studies to identify disease-relevant biomarkers, which are then used for diagnosis, prognosis, and predicting drug responses. A significant market driver is indicated by the increase in the number of research efforts in this segment.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=4438

The future is expected to bring very profitable growth prospects for both new and incumbent biobanking providers in Europe and Asia Pacific. The aforementioned can be linked to both regions' growing patient pools and rising healthcare costs

𝐌𝐚𝐢𝐧 𝐏𝐨𝐢𝐧𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬

In 2023, the biobanking market is expected to be valued at US$46.8 billion.
Biobanking demand is expected to grow at a compound annual growth rate (CAGR) of 6.6% between 2023 and 2033.
By 2033, the biobanking market is projected to grow to a value of US$ 89.5 billion.
Prime market growth drivers are the expanding frequency of chronic illnesses, rising investments in medical research and development, the growing acceptance of gene and stem cell therapies, and the growing popularity of biobanks.
The high expense of operating biobanks and the ethical and legal issues surrounding biobanking are major commercial barriers.
It is projected that Europe will continue to be a very profitable regional market for the duration of the forecast period.
It is anticipated that demand for medicinal biobanking applications will surpass supply through

"To fully realize the potential for revenue generation, biobanking companies should concentrate on reducing the operational costs of biobanks," a Fact states.MR analyst

Successful Approach

Prominent biobanking manufacturers consistently prioritize broadening their company scope to encompass new applications and geographical areas via joint ventures, alliances, procurements, and amalgamations. To realize the market's full potential in the future, businesses should concentrate on resolving the moral and legal dilemmas that beset the biobanking industry.

A thorough examination of all the tactics being used by both established and up-and-coming biobanking providers can be found in this comprehensive biobanking market study by Fact.MR, a market research and competitive intelligence service.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Top biobanking companies are concentrating on increasing their capacity and capabilities to offer a wide range of biological research data and biospecimens.

The UK Biobank, a vast repository of data on biospecimens and biomedical research, announced in May 2023 that it was to receive around US$ 162.96 million to finance its relocation to a specially constructed facility at Bruntwood SciTech's Manchester Science Park.

Biobanking Market

At a robust 6.6% CAGR, the global biobanking market is expected to reach a revenue valuation of US$ 89.5 billion by the end of the forecast period (2023 to 2033). The main markets that biobanking companies should watch out for in the future are China, the UK, and the US.

By storing and preserving biological samples like blood, tissues, and nucleic acids, biobanking plays a crucial part in improving biomedical and translational research. These samples are then made available for use in studies to identify disease-relevant biomarkers, which are then used for diagnosis, prognosis, and predicting drug responses. A significant market driver is indicated by the increase in the number of research efforts in this segment.

The future is expected to bring very profitable growth prospects for both new and incumbent biobanking providers in Europe and Asia Pacific. The aforementioned can be linked to both regions' growing patient pools and rising healthcare costs.

Main Points of the Market Analysis

In 2023, the biobanking market is expected to be valued at US$46.8 billion.
Biobanking demand is expected to grow at a compound annual growth rate (CAGR) of 6.6% between 2023 and 2033.
By 2033, the biobanking market is projected to grow to a value of US$ 89.5 billion.
Prime market growth drivers are the expanding frequency of chronic illnesses, rising investments in medical research and development, the growing acceptance of gene and stem cell therapies, and the growing popularity of biobanks.
The high expense of operating biobanks and the ethical and legal issues surrounding biobanking are major commercial barriers.
It is projected that Europe will continue to be a very profitable regional market for the duration of the forecast period.
It is anticipated that demand for medicinal biobanking applications will surpass supply through
"To fully realize the potential for revenue generation, biobanking companies should concentrate on reducing the operational costs of biobanks," a Fact states.MR analyst

Successful Approach

Prominent biobanking manufacturers consistently prioritize broadening their company scope to encompass new applications and geographical areas via joint ventures, alliances, procurements, and amalgamations. To realize the market's full potential in the future, businesses should concentrate on resolving the moral and legal dilemmas that beset the biobanking industry.

A thorough examination of all the tactics being used by both established and up-and-coming biobanking providers can be found in this comprehensive biobanking market study by Fact.MR, a market research and competitive intelligence service.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Top biobanking companies are concentrating on increasing their capacity and capabilities to offer a wide range of biological research data and biospecimens.

The UK Biobank, a vast repository of data on biospecimens and biomedical research, announced in May 2023 that it was to receive around US$ 162.96 million to finance its relocation to a specially constructed facility at Bruntwood SciTech's Manchester Science Park.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬: https://www.factmr.com/connectus/sample?flag=RC&rep_id=7181

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐁𝐢𝐨𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Storage :

Manual Biobanking
Automatic Biobanking
By Application :

Therapeutics
Clinical Diagnostics
Drug Discovery & Development
Others
By Biospecimen :

Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Others
By Product :

Biobanking Equipment
Temperature Control Systems
Freezers & Refrigerators
Cryogenic Storage Systems
Thawing Equipment
Biobanking Incubators & Centrifuges
Biobanking Alarms & Monitoring Systems
Biobanking Accessories & Other Equipment
Biobanking Consumables
Cryovialsand Cryomolds
Tubes
Others

By Region :
North America
Latin America
Europe
APAC
MEA

𝐌𝐨𝐫𝐞 𝐔𝐬𝐞𝐟𝐮𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞

With this latest product, Fact.MR offers a dispassionate evaluation of the worldwide biobanking industry, showcasing demand data from 2018 to 2022 as well as projections for the years 2023 to 2033.

The report provides a crucial analysis of the biobanking market that covers more than 30 nations, including the US, Canada, UK, Germany, France, Nordic region, Gulf Cooperation Council, Japan, Korea, and many more.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.